In fact, in order to improve costimulatory signaling, CD28-based and CD28-CD3ζ-OX40 CAR T cells are being tested in clinical trials respectively on patients with sarcoma (NCT00902044 and NCT01953900). This evidence concerns the gene CD28 and sarcoma.